Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
Effect of Empagliflozin on Body Composition and Ketones

The purpose of this study is to evaluate changes of body composition induced by Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).

hypoglycemic agents
oral hypoglycemic
type 2 diabetes mellitus
  • 3 views
  • 04 Apr, 2021
  • 1 location
The DAPA-MEMRI Trial

failure. Recently, a drug therapy (SGLT2 inhibitor therapy) in patients with diabetes was shown to benefit patients with heart failure but the mechanisms of benefit are unknown. Our hypothesis is

b-type natriuretic peptide
fasting
calcium
diabetes
electrocardiogram
  • 10 views
  • 26 Jan, 2021
  • 1 location
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.

sglt2
electrocardiogram
sglt2 inhibitor
sulfonylurea
dapagliflozin
  • 49 views
  • 25 Jan, 2021
  • 1 location
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine

glucagon
sglt2
plasma glucose
insulin sensitivity
dapagliflozin
  • 67 views
  • 11 Mar, 2021
  • 1 location
Effect of Ertugliflozin on Cardiac Function in Diabetes

The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using

  • 0 views
  • 05 Apr, 2021
  • 1 location
Dapagliflozin Heart Failure Readmission

without T2D after admission for heart failure. Treatment with SGLT2-i has been shown to reduce both heart failure hospitalizations and mortality in patients with established heart disease. However, the

b-type natriuretic peptide
diabetic ketoacidosis
diabetes
ejection fraction
dapagliflozin
  • 0 views
  • 11 Apr, 2021
  • 3 locations
Impact on Glycemic Variability After Treatment With Dapagliflozin on Type 2 Diabetes Patients

development in microvascular complications of type 2 diabetes (Brownlee and Hirsch 2006) SGLT2 inhibitors (SGLT2i) are a novel group of medications for treating type 2 diabetes patients but their effect on

continuous glucose monitoring
sglt2
dapagliflozin
sglt2 inhibitor
  • 3 views
  • 24 Mar, 2021
  • 2 locations
Renal Oxygenation Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.

perfusion, and a shift of fuel metabolites. Elucidation the mechanisms underlying the effects of SGLT2 inhibition will advance our knowledge and contribute to their optimal clinical utilization in the

  • 0 views
  • 11 Apr, 2021
  • 1 location
Antidiabetic Triple Therapy Effects on Surrogate Tests After Stroke

, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) for 6 months can reduce hsCRP in stroke patients with diabetes mellitus. Methods: This study will be conducted in

pioglitazone
diabetes mellitus
diabetes
glomerular filtration rate
ischemic stroke
  • 0 views
  • 25 Jan, 2021
  • 1 location
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

with various adverse side effects. Sodium-glucose cotransporter type-2 (SGLT2) inhibitors can reduce hepatic fat content in patients with DM. However, the role of SGLT2 inhibitors in NAFLD patients

  • 0 views
  • 06 May, 2021
  • 1 location